Hormonal
Pro-inflammatory cytokines IL-1beta and TNF-alpha are somnogenic; their expression increases with waking activity and sleep deprivation, and they promote non-rapid-eye movement (NREM) sleep and slow-wave activity (SWA).
Prioritize sleep hygiene not just for rest, but to regulate inflammation. Chronic wakefulness or poor sleep increases pro-inflammatory cytokines like IL-1beta and TNF-alpha, which can disrupt sleep architecture and overall health. Managing inflammation through lifestyle may improve sleep, and good sleep helps manage inflammation.
Pro-inflammatory cytokines tend to promote sleep and SWA while anti-inflammatory cytokines, such as IL-4, IL-10, IL-13, and IL-1 receptor antagonist (RA), tend to attenuate sleep and SWA responses induced by sleep promoting stimuli including sleep deprivation, pathogens, orpathogenic components.
Why this rating
The paper is a review citing numerous animal and human studies, but it does not present new primary clinical trial data.
Source
Neuroinflammation, Sleep, and Circadian Rhythms
Mark R. Zielinski et al. · Frontiers in Cellular and Infection Microbiology · 2022
DOI 10.3389/fcimb.2022.853096
More from this paper
- The NLRP3 inflammasome is a critical mediator of sleep regulation; its activation leads to the production of IL-1beta and IL-18, which promote NREM sleep and slow-wave activity.Good
- Circadian rhythm disruption is associated with increased morbidity risk for inflammatory diseases, including cardiovascular disease, cancer, and metabolic disease.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →